<?xml version="1.0" encoding="utf-8"?>
<Journal>
<Journal-Info>
<name>International Journal of Pharma and Bio Sciences</name>
<website>ijpbs.net</website>
<email>editorijpbs@rediffmail.com (or) editorofijpbs@yahoo.com (or) prasmol@rediffmail.com</email>
</Journal-Info>
<article>
<article-id pub-id-type='other'>10.22376/ijpbs.2019.10.1.p1-12</article-id>
<issue_number>Volume 7 Issue 4</issue_number>
<issue_period>2016 (October - December)</issue_period>
<title><b>Assets and liabilities of drug repositioning</b> </title>
<abstract>Drug discovery is an awfully tenacious job that takes an enormous amount of time, resources, and money, yet yields unsubstantial results. Drug repositioning is a method for "discovering new uses for old drugs." The main objective to repurpose a drug is to extend the application line of an existing drug, thereby narrowing the productivity gap and at the same time allows a swift reach to the market with high chances of revenues. This approach aims at new formulations, dosage, drug combination, delivery system, alternative pathways and targets, orphan diseases. Likewise the  lessThan i greaterThan de novo lessThan /i greaterThan  drug development, drug repositioning also shares many pros and cons. At one hand, drug repositioning offers relatively less risk-versus-reward ratio; on the other hand, the regulatory authority approval process, intellectual property rights and out-licensing are issues of concern. This review article will particularly focus on the various pros and cons associated with drug repositioning.</abstract>
<authors>RUPAM GILL, AMBERKAR MOHAN BABU V. AND MEENA KUMARI K.</authors>
<keywords>KEYWORDS: Chemical databases, Drug repurposing, Intellectual property rights, Off-target drug repositioning, Out-licensing</keywords>
<pages>47-53</pages>
</article>
</Journal>
